^{Bernstein JS, Dhingra O. “A phase III, single-arm, 6-month trial of a wide-dose range oral product.” Ther Adv Urol. 2024;16:1-17. 2024; doi: 10.1177/17562872241241864}

^{Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. The journal of clinical endocrinology and metabolism. 2007;92(11): 4241–4247.}

^{Layton JB, Li D, Meier CR, Sharpless JL, Stürmer T, Jick SS, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. The journal of clinical endocrinology and metabolism. 2014;99(3): 835–842.}

^{Barbonetti A, D’Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020;8(6): 1551–1566. https://doi.org/10.1111/andr.12774.}

^{Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care [Internet]. 2011;34(7):1669–75.}

^{Indirli R, Lanzi V, Arosio M, Mantovani G, Ferrante E. The association of hypogonadism with depression and its treatments. Front Endocrinol (Lausanne) [Internet]. 2023;14}

^{Rabijewski M, Papierska L, Kozakowski J, Zgliczyński W. The high prevalence of testosterone deficiency in population of Polish men over 65 years with erectile dysfunctions. Aging Male [Internet]. 2012;15(4):258–62.}

^{Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European journal of endocrinology. 2011;165(5): 675–685}

^{Sizar O, Leslie SW, Schwartz J. Male hypogonadism. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.}